The Problem

Overuse of broad spectrum antibiotics

Empiric therapy for pneumonia rules the day, because physicians do not have timely information, patients are prescribed broad-spectrum antibiotics in a “one-size-fits all”.

This promotes antibiotic resistance, unnecessary hospitalization resulting in secondary bacterial infections and high cost to the heathcare system.

The Solution

The world's first breath test to detect & monitor pulmonary infections.

The only test that can differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.

Value-Based, Cost Advantaged Product is a Win for Patient, Doctor, Hospital and Payer

The Avisa BreathTestTM is well-differentiated and a paradigm shift over sputum culture

Sputum Culture

Avisa BreathTestTM
Sensitivity
SpecificityUrease Pathogens
Point-of-Care Testing
Turnaround Time < 10 minutes
Monitor Therapy
Non-Sputum Producing Patients

Calculated total addressable market (TAM)

Disease prevalence estimates obtained from literature

223 Million Total Estimated Tests Worldwide

Including US, Europe, Japan, China

Ventilator Associated Infections
Pneumonia in the Emergency Department
Cystic Fibrosis
C. difficile
Chronic Obstructive Pulmonary
TAM By Indication

Indications for use tested in interviews with physicians, respiratory therapists, insurance plan chief medical officers and Avisa medical advisory board.

Value Based Economics of The Avisa BreathTestTM

Large U.S. hospital that admits 1,000 pneumonia patients/year in the emergency department could
save up to $4.8 million/year in
unnecessary hospital admissions.

Management Team

David Joseph

President & CEO, Co-Founder

  • 40+ yrs of experience commercializing medical devices and pharmaceuticals
  • Co-founder of four life science companies with successful exits (IPO,M&A)
  • Multiple past and present board positions

Elizabeth Perkett, MD

Consulting Chief Medical Officer

  • Professor of Pediatrics specializing in pulmonary medicine, Vanderbilt University
  • Over 50 recent scientific and clinical publications
  • Cystic Fibrosis Foundation committee member

David Karshmer

SVP, Technology Development

  • 20+ yrs of experience in medical device design
  • Founded IDEO Healthcare practice, developed numerous medical products
  • Successful serial entrepreneur (Avisa is 6th start-up company)

John Maynard

SVP, Product Management and Engineering

  • 20+ yrs experience developing medical devices based on spectroscoy
  • VP of Product Development, Engineering at VeraLight and InLight Solutions
  • 19 US patents and over 20 scientific publications

Matt Culler

VP, Finance

  • 10+ yrs investment and financial management experience
  • VP of Finance & Operations (and acting CFO) at xF Technologies
  • Venture Capital and Investment Banking experience

Graham Timmins, PhD

Co-founder of the Company

  • Associate Professor of Medicinal Chemistry at the University of New Mexico
  • Co-inventor of the Company’s patents portfolio
  • Author/co-author of over 50 publications and recipient of several federal grants
Social media & sharing icons powered by UltimatelySocial